OncoMatch/Clinical Trials/NCT06818643
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
Is NCT06818643 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies MK-3120 for advanced solid tumors.
Treatment: MK-3120 — Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids. The main goal of this study is to learn about the safety of MK-3120 and if people tolerate it.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of Alabama at Birmingham ( Site 1005) · Birmingham, Alabama
- University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1003) · Miami, Florida
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 1009) · Hackensack, New Jersey
- Virginia Commonwealth University ( Site 1008) · Richmond, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify